Abstract
The vesicular stomatitis virus cytopathic effect reduction assay is suitable to quantify polyethylene glycol-alpha interferon 2a (PEG-IFN-alpha 2a) and PEG-IFN-alpha 2b. Human serum and ribavirin did not interfere with the assay. This bioassay was successfully used for assaying PEG-IFN-alpha 2a and PEG-IFN-alpha 2b in serum samples from patients undergoing combination therapy.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antiviral Agents / blood*
-
Antiviral Agents / therapeutic use
-
Biological Assay
-
Cattle
-
Cell Line
-
Cytopathogenic Effect, Viral
-
Drug Therapy, Combination
-
Hepatitis C / blood*
-
Hepatitis C / drug therapy
-
Humans
-
Interferon alpha-2
-
Interferon-alpha / blood*
-
Interferon-alpha / therapeutic use
-
Polyethylene Glycols / therapeutic use
-
Recombinant Proteins
-
Ribavirin / pharmacology
-
Vesicular stomatitis Indiana virus / drug effects
Substances
-
Antiviral Agents
-
Interferon alpha-2
-
Interferon-alpha
-
Recombinant Proteins
-
Polyethylene Glycols
-
Ribavirin
-
peginterferon alfa-2b
-
peginterferon alfa-2a